United Therapeutics Co. (NASDAQ:UTHR) COO Sells $6,109,800.00 in Stock

United Therapeutics Co. (NASDAQ:UTHR) COO Michael Benkowitz sold 15,000 shares of the business’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $407.32, for a total value of $6,109,800.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Michael Benkowitz also recently made the following trade(s):

• On Thursday, November 7th, Michael Benkowitz sold 15,000 shares of United Therapeutics stock. The stock was sold at an average price of $401.44, for a total value of $6,021,600.00.
• On Friday, November 1st, Michael Benkowitz sold 14,700 shares of United Therapeutics stock. The stock was sold at an average price of $374.46, for a total value of $5,504,562.00.

United Therapeutics Stock Up 0.1 %

UTHR traded up $0.43 during trading on Tuesday, reaching $400.87. The company had a trading volume of 356,947 shares, compared to its average volume of 464,288. The business has a 50 day simple moving average of $359.94 and a 200-day simple moving average of $324.54. The stock has a market cap of $17.90 billion, a P/E ratio of 17.61, a PEG ratio of 1.20 and a beta of 0.56. United Therapeutics Co. has a 52 week low of $208.62 and a 52 week high of $417.82.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, beating analysts’ consensus estimates of $6.16 by $0.23. The company had revenue of $748.90 million during the quarter, compared to analysts’ expectations of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The firm’s revenue for the quarter was up 22.9% on a year-over-year basis. During the same quarter in the previous year, the company earned $5.38 earnings per share. As a group, equities research analysts expect that United Therapeutics Co. will post 25.1 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently issued reports on UTHR. Oppenheimer upped their target price on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. Jefferies Financial Group raised their price objective on shares of United Therapeutics from $315.00 to $432.00 and gave the stock a “buy” rating in a report on Monday, September 23rd. TD Cowen boosted their target price on shares of United Therapeutics from $350.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. Argus increased their price objective on shares of United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Finally, Wells Fargo & Company raised their price objective on shares of United Therapeutics from $350.00 to $380.00 and gave the stock an “overweight” rating in a report on Tuesday, August 20th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $370.86.

Hedge Funds Weigh In On United Therapeutics

Institutional investors have recently modified their holdings of the business. ClariVest Asset Management LLC boosted its stake in United Therapeutics by 120.0% in the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock worth $25,000 after buying an additional 42 shares during the last quarter. V Square Quantitative Management LLC purchased a new position in United Therapeutics in the second quarter valued at about $30,000. Innealta Capital LLC bought a new position in United Therapeutics in the 2nd quarter worth $33,000. USA Financial Formulas acquired a new stake in United Therapeutics during the third quarter valued at approximately $33,000. Finally, Capital Performance Advisors LLP acquired a new position in United Therapeutics during the 3rd quarter worth $82,000. 94.08% of the stock is owned by institutional investors and hedge funds.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.